Allergy Asthma Respir Dis.  2018 Jan;6(1):68-71. 10.4168/aard.2018.6.1.68.

Successful desensitization to fluconazole induced delayed hypersensitivity: A case report

Affiliations
  • 1Department of Internal Medicine, Kangwon National University Hospital, Chuncheon, Korea. legent@hanmail.net
  • 2Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
  • 3Department of Allergy and Clinical Immunology, Kangwon National University Hospital, Chuncheon, Korea.

Abstract

Fluconazole is a triazole-based first-generation antifungal agent and has excellent effects on candidiasis and cryptococcosis. Hypersensitivity has been reported as a side effect of fluconazole. A 76-year-old female patient used fluconazole for consolidation therapy for cryptococcal meningitis, but showed delayed hypersensitivity with skin rashes and itching sensation of the whole body. For desensitization, was attempted by administering 12-step, 1:1 fluconazole solutions were administered intravenously at sequentially increasing infusion rates. After successful quick desensitization to fluconazole, fluconazole was continuously used as a consolidation therapy for cryptococcal meningitis. We herein report a case of delayed hypersensitivity reaction to fluconazole in consolidation therpy with cryptococcal meningitis who successfully completed desensitization.

Keyword

Desensitization; Fluconazole

MeSH Terms

Aged
Candidiasis
Cryptococcosis
Exanthema
Female
Fluconazole*
Humans
Hypersensitivity
Hypersensitivity, Delayed*
Meningitis, Cryptococcal
Pruritus
Sensation
Fluconazole

Figure

  • Fig. 1. Clinical features of the fluconazole-induced delayed type hypersensitivity. There was diffuse patch eruption involving the trunk (A) and extremities (B) with itching and blanching, which continued for several days.


Cited by  1 articles

A case of rapid desensitization for rituximab-induced delayed hypersensitivity reaction
Su Ho Lee, Jae Ha Lee, Nam Hee Kim, Dong Yoon Kang, Ju Yeun Lee, Soo Jie Chung, Ji Hyun Oh, Hye-Ryun Kang
Allergy Asthma Respir Dis. 2019;7(2):109-112.    doi: 10.4168/aard.2019.7.2.109.


Reference

1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016; 62:e1–50.
Article
2. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010; 50:291–322.
Article
3. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplack DG. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. The Journal of infectious diseases. 1988; 157:178–80.
Article
4. Sugar AM, Saunders C. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquired immunodeficiency syndrome. Am J Med. 1988; 85:481–9.
Article
5. Scherer K, Brockow K, Aberer W, Gooi JH, Demoly P, Romano A, et al. Desensitization in delayed drug hypersensitivity reactions: an EAACI position paper of the Drug Allergy Interest Group. Allergy. 2013; 68:844–52.
6. Yoshizawa S, Yasuoka A, Kikuchi Y, Honda M, Gatanaga H, Tachikawa N, et al. A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma Immunol. 2000; 85:241–4.
Article
7. Kim S, Lim KH, Kang MG, Park HK, Cho SH, Min KU, et al. Successful desensitization of trimethoprim-sulfamethoxazole in Stenostrophomon-as maltophilia osteomyelitis. Allergy Asthma Respir Dis. 2014; 2:218–21.
8. Lee AR, Kim SJ, Kim J, Park JH, Lee JK, Kim JY, et al. Successful desensitization for antitubercular drugs. Allergy Asthma Respir Dis. 2013; 1:395–9.
Article
9. Yoon D, Ahn H, Kim SY, Hwang SJ, Park HK, Kang HR. Successful rapid desensitization to trimethoprim-sulfamethoxazole-induced delayed hypersensitivity. Allergy Asthma Respir Dis. 2015; 3:155–8.
Article
10. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology. 2004; 209:29–32.
Article
11. Craig TJ, Peralta F, Boggavarapu J. Desensitization for fluconazole hyper-sensitivity. J Allergy Clin Immunol. 1996; 98:845–6.
Article
12. Jariwala S, Vernon N, de Vos G. A novel method of desensitization for fluconazole hypersensitivity in a patient with AIDS. Ann Allergy Asthma Immunol. 2011; 106:542–3.
Article
13. Randolph C, Kaplan C, Fraser B. Rapid desensitization to fluconazole (Diflucan). Ann Allergy Asthma Immunol. 2008; 100:616–7.
Article
14. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxi-cology. 2005; 209:209–16.
Article
15. Hassoun-Kheir N, Bergman R, Weltfriend S. The use of patch tests in the diagnosis of delayed hypersensitivity drug eruptions. Int J Dermatol. 2016; 55:1219–24.
Article
16. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990; 12(Suppl 3):S318–26.
Article
Full Text Links
  • AARD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr